• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

    6/5/25 8:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $LIVN alert in real time by email

    This is the latest prospective evaluation of VNS Therapy in generalized tonic-clonic seizures

    Findings include 77% median seizure reduction and 43% of participants reporting seizure freedom at 24-month visits

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant epilepsy (DRE) from the CORE-VNS three-year study have been published in Epilepsia1.

    Several CORE-VNS study findings were highlighted in the recent article on GTC seizures in DRE patients who received VNS Therapy™, including:

    • At 12 months, the median reduction in GTC seizure frequency was 74%, and this reduction was sustained through 24 months with a median reduction increasing to 77%.
    • Freedom from GTC seizures (defined as the absence of GTC seizures in the three months prior to the study visit) was reported by 37% and 43% of people at the 12- and 24-month study visits, respectively, despite people having a median 10-year duration of epilepsy.
    • Approximately half of those experiencing GTC seizures were under 18 years of age, and nearly all (94%) had no history of any other previous surgery for epilepsy.
    • GTC seizure reduction was seen early, with a median 52% reduction in GTC seizure frequency at the three-month study visit.

    "GTC seizures can be some of the most severe and debilitating seizures a patient can experience," said Ana Suller Marti, M.D., Assistant Professor of Neurology at Western University in London, Ontario, Canada, and the lead author for this study. "The observed reductions in seizure frequency and severity, as well as the achievement of complete seizure freedom in some cases, are key findings that clinicians should be aware of."

    The CORE-VNS study evaluated comprehensive outcomes of real-world evidence for more than 800 epilepsy patients treated with VNS Therapy worldwide. The 115 people with drug-resistant epilepsy and generalized seizures at baseline in this analysis had a median of 10 years between epilepsy diagnosis and VNS Therapy implantation. Additionally, 90% of this participant population were under 18 years of age at the time of diagnosis.

    "I am struck by the significant seizure burden carried by the people, many of whom are so young, in this real-world dataset. Participants in this study failed a median number of six anti-seizure medications—some even as high as 20—and had a median of four tonic-clonic seizures per month at baseline," said Stephanie Bolton, LivaNova President, Global Epilepsy. "Our focus remains on contributing to the science of the treatment of epilepsy, working in partnership with physicians, and transparently communicating the latest scientific information available."

    CORE-VNS participants have been followed through the 36-month study interval, and LivaNova is currently in the process of publishing 36-month study outcomes.

    About CORE-VNS

    CORE-VNS is a real-world, long-term, open-label study focused on the outcomes of VNS Therapy™ in people diagnosed with drug-resistant epilepsy (DRE). Enrolling more than 800 people from 61 worldwide sites, the study is the most comprehensive assessment of the effectiveness of VNS Therapy to date.

    Adverse events in this published clinical trial were typical following placement of a VNS Therapy device. The most commonly reported adverse events among participants with GTCs were dysphonia, cough, neck/oropharyngeal pain, and general discomfort. See important safety information at VNSTherapy.com/safety.

    About VNS Therapy™ for Epilepsy

    VNS Therapy is clinically proven safe and effective as an add-on treatment to reduce the frequency of seizures in adults and children as young as 4 years old with drug-resistant epilepsy and partial onset seizures. It is a unique treatment approach developed for people with drug-resistant epilepsy—a condition that affects approximately one in three people with epilepsy. Unlike some other surgical treatment options for people with drug-resistant epilepsy, VNS Therapy implantation involves an outpatient procedure and does not require penetration of the skull. Outside the United States, the VNS Therapy indications for use may vary.

    VNS Therapy has not been approved by the U.S. Food and Drug Administration (FDA) for use in primary generalized seizures, and the safety and effectiveness of VNS Therapy for the reduction of primary generalized seizures has not been established.

    The VNS Therapy system is contraindicated for use in patients with a bilateral or left cervical vagotomy.

    Do not use shortwave diathermy, microwave diathermy, or therapeutic ultrasound diathermy (hereafter referred to as diathermy) on patients implanted with a VNS Therapy System.

    VNS Therapy indications for use vary by geographic location. Consult your local labeling. VNS Therapy Global Physician Manuals.

    For more information, visit VNSTherapy.com.

    References

    1

    Suller Marti A, Verner R, Keezer M, et al. Reduction of generalized tonic-clonic seizures following vagus nerve stimulation therapy: CORE-VNS Study 24-month follow-up. Epilepsia. Published online April 1, 2025. doi:10.1111/epi.18371

    About LivaNova

    LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.

    Safe Harbor Statement

    This news release contains "forward-looking statements" concerning the Company's goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the CORE-VNS study or VNS Therapy. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250605820123/en/

    LivaNova Investor Relations and Media Contacts

    +1 281-895-2382

    Briana Gotlin

    VP, Investor Relations

    [email protected]

    Deanna Wilke

    VP, Corporate Communications

    [email protected]

    Get the next $LIVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LIVN

    DatePrice TargetRatingAnalyst
    5/20/2025$60.00Peer Perform → Outperform
    Wolfe Research
    2/26/2025Outperform → Peer Perform
    Wolfe Research
    10/4/2024$65.00Buy
    Goldman
    9/17/2024$55.00 → $66.00Neutral → Outperform
    Robert W. Baird
    3/20/2024Buy
    Needham
    2/20/2024$60.00 → $70.00Neutral → Buy
    Mizuho
    9/6/2023$52.00Hold
    HSBC Securities
    7/19/2023$56.00Neutral
    Robert W. Baird
    More analyst ratings

    $LIVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LivaNova upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded LivaNova from Peer Perform to Outperform and set a new price target of $60.00

      5/20/25 8:01:26 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova downgraded by Wolfe Research

      Wolfe Research downgraded LivaNova from Outperform to Peer Perform

      2/26/25 7:12:54 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Goldman initiated coverage on LivaNova with a new price target

      Goldman initiated coverage of LivaNova with a rating of Buy and set a new price target of $65.00

      10/4/24 7:42:40 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

      Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study, evaluating comprehensive outcomes of real-world evidence for more than 800 people with epilepsy treated with VNS Therapy™ worldwide. With the clinical study report (CSR) now complete, the final 36-month data further validate the effectiveness of VNS Therapy for severe focal seizures in both children and adults with drug-resistant epilepsy (DRE) and demonstrate early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures. "It is c

      6/5/25 8:15:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

      This is the latest prospective evaluation of VNS Therapy in generalized tonic-clonic seizures Findings include 77% median seizure reduction and 43% of participants reporting seizure freedom at 24-month visits LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant epilepsy (DRE) from the CORE-VNS three-year study have been published in Epilepsia1. Several CORE-VNS study findings were highlighted in the recent article on GTC seizures in DRE patients who received VNS Therapy™, including: At 12 months, the median reduction in GTC seizure frequency was 74%, and t

      6/5/25 8:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

      Final critical papers on RECOVER clinical study data accepted, supporting the Company's submission for coverage reconsideration Strong 24-month top-line data for RECOVER clinical study demonstrates durability of VNS Therapy In-depth analysis on suicidality at 12 months yields positive results LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it has initiated the process with the U.S. Centers for Medicare and Medicaid Services (CMS) to seek reconsideration of national Medicare coverage for VNS Therapy™ in unipolar patients with treatment-resistant depression (TRD). The first step in the process for making a National Coverage Determination (NCD)

      6/4/25 8:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    Financials

    Live finance-specific insights

    See more
    • LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

      Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue guidance; updated full-year 2025 guidance now incorporates impact of SNIA decision and currently applicable tariffs Completed premarket approval submission for the aura6000™ System intended to treat obstructive sleep apnea Announced 12-month, top-line OSPREY data demonstrating strong response and sustained therapeutic impact for patients who received proximal hypoglossal nerve stimulation for obstructive sleep apnea LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the first quarter

      5/7/25 6:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova to Announce First-Quarter 2025 Results

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2025 results on Wednesday, May 7, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 047836. A replay will be available on the LivaN

      3/26/25 8:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $321.8 million increased 3.8% on a reported basis, 4.7% on a constant-currency basis, and 6.8% on an organic basis as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share of $1.02 and adjusted diluted earnings per share of $0.81 Full-year 2024 revenue of $1.25 billion increased 8.7% on a reported basis, 9.3% on a constant-currency basis, and 10.7% on an organic basis as compared to the prior-year Full-year 2024 U.S. GAAP

      2/25/25 6:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    Leadership Updates

    Live Leadership Updates

    See more
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate
    • LivaNova Appoints Susan Podlogar as a New Director

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee for the Board. "LivaNova's Board of Directors is pleased to welcome Susan Podlogar," said William Kozy, Chair of the Board. "Susan is a visionary leader with three decades of experience in leading business, talent, and cultural transformations at recognized global companies. She possesses a sharp understanding of the ever-changing global business landscape and will be a tremendous asset to the Board." Podlogar's career spans 30 years, holding key g

      10/8/24 9:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will accelerate the Company's development of new technologies. In this capacity, Tezel will join the LivaNova Executive Leadership Team. "I am very pleased to welcome Ahmet to the LivaNova team. At LivaNova, our commitment to pioneering innovation remains unwavering, and Ahmet's arrival marks a significant step in advanci

      4/30/24 9:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    SEC Filings

    See more
    • SEC Form SD filed by LivaNova PLC

      SD - LivaNova PLC (0001639691) (Filer)

      5/29/25 4:05:39 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova PLC filed SEC Form 8-K: Regulation FD Disclosure

      8-K - LivaNova PLC (0001639691) (Filer)

      5/21/25 4:08:06 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by LivaNova PLC

      SCHEDULE 13G/A - LivaNova PLC (0001639691) (Subject)

      5/13/25 4:00:17 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by LivaNova PLC

      SC 13G - LivaNova PLC (0001639691) (Subject)

      4/17/24 4:19:05 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by LivaNova PLC (Amendment)

      SC 13G/A - LivaNova PLC (0001639691) (Subject)

      2/12/24 4:01:13 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by LivaNova PLC (Amendment)

      SC 13G/A - LivaNova PLC (0001639691) (Subject)

      1/23/24 11:52:27 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LIVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Innovation Officer Tezel Ahmet

      4 - LivaNova PLC (0001639691) (Issuer)

      4/1/25 9:01:37 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President, Global Epilepsy Bolton Stephanie converted options into 6,024 units of Ordinary Shares and covered exercise/tax liability with 2,835 units of Ordinary Shares, increasing direct ownership by 33% to 12,751 units (SEC Form 4)

      4 - LivaNova PLC (0001639691) (Issuer)

      4/1/25 9:01:28 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Makatsaria Vladimir converted options into 9,330 units of Ordinary Shares and covered exercise/tax liability with 5,046 units of Ordinary Shares (SEC Form 4)

      4 - LivaNova PLC (0001639691) (Issuer)

      4/1/25 9:01:18 PM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care